US Stock Market Move | Aktis Oncology (AKTS.US) listed on the US stock market, opening price increased by over 49%.

On Friday, Aktis Oncology (AKTS.US) debuted on the US stock market with the opening stock price rising. As of the time of writing, the stock has surged over 49%, reaching $26.88. The IPO price was $18. Aktis Oncology is a clinical-stage oncology company focused on developing alpha particle radiopharmaceuticals for common solid tumors. Its pipeline includes Ac-AKY-1189 targeting Nectin-4 expressing cancers, which is currently undergoing a multicenter Phase 1b clinical trial in the US with approximately 150 patients recruited, preliminary results expected to be disclosed in the first quarter of 2027; and Ac-AKY-2519 targeting tumors expressing B7-H3, planned to submit an Investigational New Drug application (IND) in 2026.